bioMerieux S.A.

bioMerieux S.A.

0RUG · LSE

93.08EUR+0.35 (+0.38%)

Price History

Full chart

Market Stats

Previous Close92.73
Open92.50
Day Range92.35 – 93.08
52-Week Range65.90 – 115.00
Volume2.28K
Market Cap12.30B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.74%
Beta0.58
50-Day Avg93.95
200-Day Avg95.32

About

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.

Company Details

  • CEOMr. Pierre Boulud
  • Employees14.56K
  • Headquarters376 Chemin De l?Orme, Marcy-l'Étoile, France, 69280, UK
  • Websitehttps://www.biomerieux.com

Leadership

  • Mr. Pierre BouludChief Executive Officer · b. 1971
  • Mr. Guillaume BouhoursExecutive VP of Finance, Purchasing and Information Systems & CFO · b. 1976
  • Aymeric FichetHead of Investor Relations
  • Ms. Audrey DauvetExecutive Vice President of Legal, Corporate Integrity & Public Affairs · b. 1975
  • Ms. Valerie LeyldeExecutive Vice President of Human Resources, Communications & CSR
  • Mr. Pierre CharbonnierExecutive Vice President of Global Quality, Manufacturing & Supply Chain
  • Mr. Yasha MitrottiExecutive Vice President of Industrial Applications
  • Mr. Frederic BesemeHead of CSR · b. 1956
  • Ms. Jennifer ZinnExecutive Vice President of Clinical Operations
  • Dr. Charles K. CooperExecutive VP of Medical Affairs & Chief Medical Officer

Financials

Income Statement

Currency: EUR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Total Revenue2.10B2.29B2.42B2.67B3.12B--
Growth (%)-+8.80%+5.82%+10.47%+16.58%--
Cost of Revenue1.00B1.08B1.12B1.21B1.36B--
Gross Profit1.10B1.21B1.30B1.47B1.75B--
Gross Margin52.33%52.96%53.79%54.83%56.24%--
Operating Expense819.10M897.10M956.20M1.10B1.20B--
Operating Income281.60M314.70M346.10M370.70M552.20M--
Operating Margin13.39%13.75%14.29%13.86%17.71%--
Net Income179.20M238.20M253.70M272.90M404.30M--
Net Income Margin8.52%10.41%10.48%10.20%12.97%--
Interest Expense000000-
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%--

Balance Sheet

Currency: EUR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Total Assets3.03B2.99B3.50B3.78B3.93B--
Total Liabilities1.41B1.25B1.57B1.58B1.50B--
Total Equity1.62B1.74B1.93B2.20B2.43B--
Cash41.50M97.70M48.40M34.00M75.70M--
Total Debt365.40M391.10M524.90M153.70M352.40M--

Cash Flow

Currency: EUR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow335.60M341.30M399.80M407.90M582.80M811.10M475.10M--
Investing Cash Flow-257.20M-180.40M-413.10M-282.20M-265.20M-307.30M-528.10M--
Financing Cash Flow-52.50M-52.50M43.00M-133.90M-176.20M-127.00M-244.20M--
Capital Expenditure233.00M183.50M226.40M272.50M277.50M290.10M286.70M00
Dividends Paid39.50M39.40M40.20M41.30M22.50M73.10M101.20M--

Earnings

Report DateFeb 25, 2027
EPS Estimate-
EPS Actual-
Surprise-
TimingPre-market

Key Statistics & Ratios

Market Cap12.30B
Enterprise Value8.99B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.00
Book Value36.51
Revenue (TTM)3.99B
Gross Profit (TTM)2.24B
EBITDA1.05B
Profit Margin11.59%
Operating Margin15.23%
Return on Equity11.22%
Return on Assets7.23%
Shares Outstanding0
Shares Float40.02M
Beta0.58
Dividend Yield0.74%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20261×
0.98Jun 9, 2026
20251×
0.90Jun 9, 2025
20241×
0.85Jun 7, 2024
20231×
0.85Jun 6, 2023
20221×
0.85Jun 6, 2022
20211×
0.62Jun 4, 2021
20201×
0.19Jul 14, 2020
20191×
0.35Jun 4, 2019
20181×
0.34Jun 5, 2018
20171×
0.33Jun 6, 2017
20161×
0.33Jun 7, 2016
20151×
0.33Jun 5, 2015
20141×
0.33Jun 3, 2014
20131×
0.33Jun 4, 2013
20121×
0.33Jun 1, 2012
20111×
0.33Jun 17, 2011
20101×
0.31Jun 14, 2010
20091×
0.27Jun 15, 2009

Stock Splits

  • Sep 20, 2017959692:319897